SERIAL DENSITY ANALYSIS OF HEPATITIS-C VIRUS PARTICLE-POPULATIONS IN CHRONIC HEPATITIS-C PATIENTS TREATED WITH INTERFERON-ALPHA

被引:16
作者
KANTO, T [1 ]
HAYASHI, N [1 ]
TAKEHARA, T [1 ]
HAGIWARA, H [1 ]
MITA, E [1 ]
OSHITA, M [1 ]
KATAYAMA, K [1 ]
KASAHARA, A [1 ]
FUSAMOTO, H [1 ]
KAMADA, T [1 ]
机构
[1] OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN
关键词
HCV DENSITY; ULTRACENTRIFUGATION; INTERFERON-ALPHA; IMMUNE COMPLEX; NEUTRALIZATION;
D O I
10.1002/jmv.1890460311
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In interferon treatment of chronic hepatitis C patients, the biochemical and virological responses mostly parallel each other. However, some patients who show persistent ALT normalization display continued viremia after cessation of therapy. High-density hepatitis C virus (HCV) particles, which are immune complex forms, are reported to be less infectious both in vitro and in vivo. To assess whether high-density HCV contributes to the response discrepancies and to clarify the association with patient outcome, sera were examined from chronic hepatitis C patients who were treated with interferon-cu. This study included 10 sustained responders with viremia (SR + ve), 5 SR without viremia, 3 transient responders (TR), and 3 nonresponders (NR). The SR + ve patients were defined as those with continued ALT normalization and serum HCV-RNA positivity at 24 weeks after therapy completion. Serum samples obtained before and 24 weeks after therapy were ultracentrifuged on 35% sucrose. The ratio between high-density and low-density HCV was determined by quantification of HCV-RNA titers in the bottom and top fractions by competitive reverse transcription and by the polymerase chain reaction, and expressed as the bottom/top (B/T) ratio. The B/T ratios before therapy were 1:1 in all groups of patients, and 1:1 after therapy in TR and NR groups. Five out of 6 SR + ve patients who showed 1:1 ratio after-therapy relapsed within 1 year. in contrast, all SR + ve patients whose ratios were 10-100:1 continued to show ALT normalization. These findings demonstrate that patients who have high-density HCV dominance after therapy show persistent ALT normalization despite viremia, which can be explained by predominance of the neutralized immune complex. (C) 1995 Wiley-Liss. Inc.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 28 条
  • [1] DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS
    ALTER, HJ
    PURCELL, RH
    SHIH, JW
    MELPOLDER, JC
    HOUGHTON, M
    CHOO, QL
    KUO, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1494 - 1500
  • [2] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506
  • [3] RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DIBISCEGLIE, AM
    MARTIN, P
    KASSIANIDES, C
    LISKERMELMAN, M
    MURRAY, L
    WAGGONER, J
    GOODMAN, Z
    BANKS, SM
    HOOFNAGLE, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1506 - 1510
  • [4] DETECTION OF HEPATITIS-C-VIRUS RNA IN CHRONIC NON-A, NON-B LIVER-DISEASE
    HAGIWARA, H
    HAYASHI, N
    MITA, E
    HIRAMATSU, N
    UEDA, K
    TAKEHARA, T
    YUKI, N
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    [J]. GASTROENTEROLOGY, 1992, 102 (02) : 692 - 694
  • [5] DETECTION OF HEPATITIS-C VIRUS-RNA IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS-C TREATED WITH INTERFERON-ALPHA
    HAGIWARA, H
    HAYASHI, N
    MITA, E
    UEDA, K
    TAKEHARA, T
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    [J]. HEPATOLOGY, 1992, 15 (01) : 37 - 41
  • [6] QUANTITATIVE-ANALYSIS OF HEPATITIS-C VIRUS-RNA IN SERUM DURING INTERFERON ALFA THERAPY
    HAGIWARA, H
    HAYASHI, N
    MITA, E
    TAKEHARA, T
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    [J]. GASTROENTEROLOGY, 1993, 104 (03) : 877 - 883
  • [7] DYNAMICS OF GENOME CHANGE IN THE E2/NS1 REGION OF HEPATITIS-C VIRUS IN-VIVO
    HIGASHI, Y
    KAKUMU, S
    YOSHIOKA, K
    WAKITA, T
    MIZOKAMI, M
    OHBA, K
    ITO, Y
    ISHIKAWA, T
    TAKAYANAGI, M
    NAGAI, Y
    [J]. VIROLOGY, 1993, 197 (02) : 659 - 668
  • [8] EQUILIBRIUM CENTRIFUGATION STUDIES OF HEPATITIS-C VIRUS - EVIDENCE FOR CIRCULATING IMMUNE-COMPLEXES
    HIJIKATA, M
    SHIMIZU, YK
    KATO, H
    IWAMOTO, A
    SHIH, JW
    ALTER, HJ
    PURCELL, RH
    YOSHIKURA, H
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (04) : 1953 - 1958
  • [9] COMPARATIVE EFFICACY OF INTERFERON-ALFA IN CIRRHOTIC AND NONCIRRHOTIC PATIENTS WITH NON-A, NON-B, C HEPATITIS
    JOUET, P
    ROUDOTTHORAVAL, F
    DHUMEAUX, D
    METREAU, JM
    CALMUS, Y
    POUPON, R
    JOUANOLLE, H
    MIGUET, JP
    BRECHOT, C
    PAYEN, JL
    CALES, P
    TRAN, A
    BEAUGRAND, M
    CAPRON, JP
    ZARSKI, JP
    DOFFOEL, M
    PARIENTE, EA
    LEMONNIER, C
    [J]. GASTROENTEROLOGY, 1994, 106 (03) : 686 - 690
  • [10] KANTO T, 1994, HEPATOLOGY, V19, P296